Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection

Table 4 Univariate analysis of prognostic factors for recurrence-free survival and overall survival

Variables	RFS		OS
	P value	HR (95%CI)	P value	HR (95%CI)
Age (≤ 68 yr vs > 68 yr)	0.025	2.07 (1.10-3.91)	0.058	2.46 (0.97-6.23)
Sex (female vs male)	0.658	1.19 (0.56-2.53)	0.078	2.38 (0.91-6.22)
Tumor location
Body		1.00		1.00
Fundus	0.788	0.76 (0.10-5.72)	0.961	0.85 (0.18-6.62)
Antrum	0.869	0.94 (0.48-1.85)	0.591	1.30 (0.50-3.35)
Multiple	0.009	5.15 (1.50-17.72)	0.973	1.10 (0.15-7.54)
Pathology
PCA/TAC		1.00		1.00
PDAC	0.591	1.22 (0.59-2.53)	0.643	0.76 (0.24-2.41)
SRC/MAC	0.182	1.86 (0.75-4.64)	0.457	1.62 (0.45-5.83)
Lauren classification (intestinal vs non-intestinal)	0.368	1.35 (0.70-2.62)	> 0.999	1.00 (0.39-2.53)
T stage
T1		1.00		1.00
T2	0.005	4.97 (1.62-15.21)	0.300	2.83 (0.40-20.24)
T3	< 0.001	9.78 (3.34-28.64)	0.008	9.86 (1.80-53.93)
T4	< 0.001	34.10 (12.24-94.94)	< 0.001	52.24 (11.13-245.23)
Lymph node metastasis (absence vs presence)	< 0.001	11.14 (5.08-24.44)	< 0.001	13.62 (3.93-47.22)
Tumor size (≤ 3.0 cm vs > 3.0 cm)	< 0.001	5.50 (2.30-13.19)	0.006	17.13 (2.27-128.96)
Tumor involvement of resection margin (negative vs positive)	0.013	4.48 (1.38-14.60)	0.018	5.87 (1.35-25.56)
White blood cell (≤ 9.5 × 1012 cells/L vs > 9.5 × 1012 cells/L)	0.006	2.73 (1.32-5.62)	0.910	0.92 (0.21-3.99)
Hemoglobin (≤ 12.0 g/dL vs > 12.0 g/dL)	< 0.001	0.25 (0.13-0.48)	< 0.001	0.12 (0.05-0.31)
NLR (≤ 2.10 vs > 2.10)	0.002	4.04 (1.96-8.33)	0.117	2.13 (0.83-5.51)
PLR (≤ 210.0 vs > 210.0)	< 0.001	4.03 (2.03-7.99)	0.005	4.12 (1.55-10.98)
Albumin (≤ 3.9 g/dL vs > 3.9 g/dL)	0.001	0.27 (0.14-0.52)	0.003	0.23 (0.09-0.60)
CRP (≤ 20.0 mg/dL vs > 20.0 mg/dL)	0.013	2.49 (1.21-5.14)	0.306	1.79 (0.59-5.49)
FDG uptake (negative vs positive)	< 0.001	7.82 (3.05-20.07)	0.004	19.68 (2.61-148.27)
Tmax (≤ 6.0 vs > 6.0)1	< 0.001	5.72 (3.01-10.86)	0.002	5.35 (1.88-15.21)
BM SUV (≤ 1.50 vs > 1.50)	0.016	2.27 (1.16-4.45)	0.196	1.87 (0.72-4.84)
BLR (≤ 0.72 vs > 0.72)	< 0.001	8.25 (3.22-21.15)	0.003	20.69 (2.75-155.64)

¹Analyzed in 156 patients with positive FDG uptake. RFS: Recurrence-free survival; OS: Overall survival; PAC: Papillary adenocarcinoma; TAC: Tubular adenocarcinoma; PDAC: Poorly-differentiated adenocarcinoma; SRC: Signet-ring cell carcinoma; MAC: Mucinous adenocarcinoma; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; FDG: F-18 fluorodexoyglucose; PET/CT: Positron emission tomography/computed tomography; BM: Bone marrow; BLR: BM-to-liver uptake ratio.